Strategic consensus on heart failure in Portugal launched

News & Events

6 October 2020
AUTHOR: HFPN Admin

The HFPN has collaborated with the Institute of Health Sciences of the Catholic University of Portugal (UCP) to develop a strategic consensus on heart failure in Portugal. The document highlights existing gaps and presents specific measures to address the challenge.

The UCP put together a working group to develop the consensus. This included cardiologists, internists, general practitioners, nurses, pharmacists, public health specialists, patient representatives, policymakers and industry representatives. The group met three times during 2019: first to discuss the current situation in Portugal regarding heart failure; secondly to focus on care models and potential measures to address the challenge; and finally to define the level of consensus on the measures proposed.

During 2020, the report of the consensus was revised in light of the COVID-19 pandemic, which has inevitably led to reprioritisation of several elements of healthcare and policy.

HFPN Head of Programme Sara C Marques led the scientific coordination and write-up of the work. The report is currently available in Portuguese, with an English translation planned in the near future.

To find out more and read the consensus report, visit http://coracaodeportugal.dn.pt/o-consenso-estrategico-para-a-ic/

Tagged:

More from News & Events

Strategic consensus on heart failure in Portugal launched
Strategic consensus on heart failure in Portugal launched...
06 October 2020
The HFPN has collaborated with the Institute of Health Sciences of the Catholic University of Portugal to develop a strategic consensus on heart failure in Portugal....
Read article
HFPN presents Portuguese work at Portuguese Society of Cardi
HFPN presents Portuguese work at Portuguese Society of Cardi...
24 January 2020
The HFPN presented recent work at the Annual Meeting of the Heart Failure Study Group of the Portuguese Society of Cardiology....
Read article
The Heart Failure Policy Network is made possible with financial support from Novartis Pharma, AstraZeneca and Vifor Pharma. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.